US Patent Issued to Bacainn Biotherapeutics on March 17 for "Probenecid compounds for the treatment of inflammasome-mediated lung disease" (Massachusetts, Missouri Inventors)

ALEXANDRIA, Va., March 17 -- United States Patent no. 12,577,211, issued on March 17, was assigned to Bacainn Biotherapeutics Ltd. (George Town, Cayman Islands).

"Probenecid compounds for the treatment of inflammasome-mediated lung disease" was invented by Chris Murphy (Upton, Mass.), Ronald Farquhar (Boston), Roland E. Dolle (Eureka, Mo.) and Manuel Navia (Lexington, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed herein are methods, compounds, and compositions for treating or preventing inflammasome-mediated diseases or conditions, including inflammasome-mediated lung diseases or conditions."

The patent was filed on June 24, 2021, under Application No. 18/013,355.

*For further information,...